
Zenotech (ZENOTECH) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
86.4M
Gross Profit
86.4M
100.00%
Operating Income
6.9M
7.97%
Net Income
9.9M
11.45%
EPS (Diluted)
₹0.16
Balance Sheet Metrics
Total Assets
1.1B
Total Liabilities
149.0M
Shareholders Equity
961.3M
Debt to Equity
0.15
Cash Flow Metrics
Revenue & Profitability Trend
Zenotech Income Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Revenue | 389.8M | 367.6M | 383.5M | 324.9M | 193.7M |
Cost of Goods Sold | 8.4M | 42.0M | 35.7M | 25.5M | 23.9M |
Gross Profit | 381.4M | 325.6M | 347.8M | 299.4M | 169.8M |
Gross Margin % | 97.8% | 88.6% | 90.7% | 92.1% | 87.7% |
Operating Expenses | |||||
Research & Development | - | - | - | - | - |
Selling, General & Administrative | - | 11.9M | 9.9M | 9.2M | 6.9M |
Other Operating Expenses | 156.5M | 73.4M | 80.3M | 75.5M | 57.4M |
Total Operating Expenses | 156.5M | 85.3M | 90.2M | 84.6M | 64.3M |
Operating Income | 72.2M | 61.0M | 94.6M | 64.2M | -31.5M |
Operating Margin % | 18.5% | 16.6% | 24.7% | 19.8% | -16.2% |
Non-Operating Items | |||||
Interest Income | - | 9.5M | 3.7M | 986.0K | 547.0K |
Interest Expense | 0 | 0 | 1.1M | 12.2M | 15.5M |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | 106.9M | 111.4M | 145.0M | 99.0M | -12.2M |
Income Tax | 50.8M | 28.4M | 29.2M | -122.7M | 0 |
Effective Tax Rate % | 47.5% | 25.5% | 20.1% | -124.0% | 0.0% |
Net Income | 56.1M | 83.0M | 115.9M | 221.8M | -12.2M |
Net Margin % | 14.4% | 22.6% | 30.2% | 68.2% | -6.3% |
Key Metrics | |||||
EBITDA | 157.3M | 182.6M | 217.3M | 180.1M | 65.0M |
EPS (Basic) | ₹0.92 | ₹1.36 | ₹1.90 | ₹3.63 | ₹-0.20 |
EPS (Diluted) | ₹0.92 | ₹1.36 | ₹1.90 | ₹3.63 | ₹-0.20 |
Basic Shares Outstanding | 61009783 | 61030568 | 61030568 | 61030568 | 61030568 |
Diluted Shares Outstanding | 61009783 | 61030568 | 61030568 | 61030568 | 61030568 |
Income Statement Trend
Zenotech Balance Sheet From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 265.8M | 18.2M | 111.4M | 24.1M | 24.6M |
Short-term Investments | 13.2M | 178.9M | 6.8M | 1.6M | 1.4M |
Accounts Receivable | 74.5M | 32.5M | 33.2M | 39.3M | 38.0M |
Inventory | 0 | 8.4M | 0 | 608.0K | 619.0K |
Other Current Assets | 6.4M | 7.9M | 11.2M | 8.1M | 8.8M |
Total Current Assets | 359.9M | 261.6M | 162.6M | 73.7M | 73.5M |
Non-Current Assets | |||||
Property, Plant & Equipment | 608.7M | 20.9M | 19.9M | 18.2M | 17.6M |
Goodwill | - | - | - | - | - |
Intangible Assets | - | - | - | - | - |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 923.0K | -51.0K | 1.0K | 1.0K | 1.0K |
Total Non-Current Assets | 750.4M | 800.4M | 846.1M | 867.1M | 785.0M |
Total Assets | 1.1B | 1.1B | 1.0B | 940.8M | 858.4M |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 25.2M | 28.1M | 34.8M | 20.7M | 19.2M |
Short-term Debt | - | - | - | 0 | 0 |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 15.6M | 10.6M | 11.2M | 11.8M | 11.0M |
Total Current Liabilities | 125.9M | 135.2M | 166.1M | 155.8M | 149.5M |
Non-Current Liabilities | |||||
Long-term Debt | 0 | 0 | 0 | 60.0M | 206.6M |
Deferred Tax Liabilities | - | - | - | - | - |
Other Non-Current Liabilities | 944.0K | 9.7M | 9.7M | 9.8M | 10.0M |
Total Non-Current Liabilities | 23.1M | 21.4M | 20.0M | 78.7M | 224.9M |
Total Liabilities | 149.0M | 156.6M | 186.0M | 234.4M | 374.4M |
Equity | |||||
Common Stock | 610.3M | 610.3M | 610.3M | 610.3M | 610.3M |
Retained Earnings | - | -1.8B | -1.9B | -2.0B | -2.2B |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 961.3M | 905.4M | 822.7M | 706.4M | 484.1M |
Key Metrics | |||||
Total Debt | 0 | 0 | 0 | 60.0M | 206.6M |
Working Capital | 234.0M | 126.4M | -3.4M | -82.0M | -76.0M |
Balance Sheet Composition
Zenotech Cash Flow Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 106.9M | 111.4M | 145.0M | 99.0M | -12.2M |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | - | - | - | - | - |
Working Capital Changes | -23.0M | -19.6M | -11.0M | 5.6M | 11.3M |
Operating Cash Flow | 69.8M | 82.4M | 131.5M | 115.8M | 14.1M |
Investing Activities | |||||
Capital Expenditures | -38.6M | -42.3M | -61.9M | -19.4M | -49.1M |
Acquisitions | - | - | - | - | - |
Investment Purchases | - | - | - | - | - |
Investment Sales | - | - | - | - | - |
Investing Cash Flow | -38.6M | -42.3M | -61.9M | -19.4M | -48.7M |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | - | - | - | - | - |
Debt Issuance | - | - | - | 0 | 20.0M |
Debt Repayment | 0 | 0 | -60.0M | -146.6M | 0 |
Financing Cash Flow | 0 | 0 | -60.0M | -146.6M | 20.0M |
Free Cash Flow | 56.3M | 75.9M | 144.3M | 157.3M | 8.3M |
Net Change in Cash | 31.2M | 40.1M | 9.6M | -50.2M | -14.7M |
Cash Flow Trend
Zenotech Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
63.79
Price to Book
3.55
Price to Sales
8.36
PEG Ratio
-2.68
Profitability Ratios
Profit Margin
13.11%
Operating Margin
13.84%
Return on Equity
5.84%
Return on Assets
5.06%
Financial Health
Current Ratio
2.86
Debt to Equity
0.00
Beta
-0.09
Per Share Data
EPS (TTM)
₹0.87
Book Value per Share
₹15.63
Revenue per Share
₹6.63
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
zenotech | 3.4B | 63.79 | 3.55 | 5.84% | 13.11% | 0.00 |
Sun Pharmaceutical | 4.0T | 38.23 | 5.50 | 15.08% | 19.29% | 3.26 |
Divi's Laboratories | 1.6T | 70.92 | 10.91 | 14.64% | 23.89% | 0.03 |
Sun Pharma Advanced | 47.4B | -13.85 | -21.83 | 157.88% | -53.22% | -1.24 |
Aarti Drugs | 44.1B | 23.41 | 3.22 | 12.28% | 7.80% | 44.92 |
Sequent Scientific | 43.7B | 153.36 | 6.20 | 2.84% | 1.85% | 62.47 |
Financial data is updated regularly. All figures are in the company's reporting currency.